Quality of Life After Intravenous Thrombolysis for Acute Ischemic Stroke: Results From the AcT Randomized Controlled Trial
Tolulope T. Sajobi,Olayinka I. Arimoro,Ayoola Ademola,Nishita Singh,Fouzi Bala,Mohammed A. Almekhlafi,Yan Deschaintre,Shelagh B. Coutts,Sibi Thirunavukkarasu,Houman Khosravani,Ramana Appireddy,François Moreau,Gordon J. Gubitz,Aleksander Tkach,Luciana Catanese,Dar Dowlatshahi,George Medvedev,Jennifer Mandzia,Aleksandra Pikula,Jai Shiva Shankar,Heather Williams,Thalia S. Field,Alejandro Manosalva,Muzaffar Siddiqui,Atif Zafar,Oje Imoukhuede,Gary Hunter,Andrew M. Demchuk,Sachin M. Mishra,Laura C. Gioia,Shirin Jalini,Caroline Cayer,Stephen J. Phillips,Elsadig Elamin,Ashkan Shoamanesh,Suresh Subramaniam,Mahesh P. Kate,Gregory Jacquin,Marie-Christine Camden,Faysal Benali,Ibrahim Alhabli,MacKenzie Horn,Grant Stotts,Michael D. Hill,David J. Gladstone,Alexandre Y. Poppe,Arshia Sehgal,Qiao Zhang,Brendan Lethebe,Craig Doram,Michel Shamy,Carol Kenney,Brian H. Buck,Richard H. Swartz,Bijoy K. Menon
DOI: https://doi.org/10.1161/strokeaha.123.044690
IF: 10.17
2024-01-28
Stroke
Abstract:Stroke, Ahead of Print. BACKGROUND:Recent evidence from thrombolysis trials indicates the noninferiority of intravenous tenecteplase to intravenous alteplase with respect to good functional outcomes in patients with acute stroke. We examined whether the health-related quality of life (HRQOL) of patients with acute stroke differs by the type of thrombolysis treatment received. In addition, we examined the association between the modified Rankin Scale score 0 to 1 and HRQOL and patient-reported return to prebaseline stroke functioning at 90 days.METHODS:Data were from all patients included in the AcT trial (Alteplase Compared to Tenecteplase), a pragmatic, registry-linked randomized trial comparing tenecteplase with alteplase. HRQOL at 90-day post-randomization was assessed using the 5-item EuroQOL questionnaire (EQ5D), which consists of 5 items and a visual analog scale (VAS). EQ5D index values were estimated from the EQ5D items using the time tradeoff approach based on Canadian norms. Tobit regression and quantile regression models were used to evaluate the adjusted effect of tenecteplase versus alteplase treatment on the EQ5D index values and VAS score, respectively. The association between return to prebaseline stroke functioning and the modified Rankin Scale score 0 to 1 and HRQOL was quantified using correlation coefficient (r) with 95% CI.RESULTS:Of 1577 included in the intention-to-treat analysis patients, 1503 (95.3%) had complete data on the EQ5D. Of this, 769 (51.2%) were administered tenecteplase and 717 (47.7%) were female. The mean EQ5D VAS score and EQ5D index values were not significantly higher for those who received intravenous tenecteplase compared with those who received intravenous alteplase (P=0.10). Older age (P<0.01), more severe stroke assessed using the National Institutes of Health Stroke Scale (P<0.01), and longer stroke onset-to-needle time (P=0.004) were associated with lower EQ5D index and VAS scores. There was a strong association (r, 0.85 [95% CI, 0.81–0.89]) between patient-reported return to prebaseline functioning and modified Rankin Scale score 0 to 1 Similarly, there was a moderate association between return to prebaseline functioning and EQ5D index (r, 0.45 [95% CI, 0.40–0.49]) and EQ5D VAS scores (r, 0.42 [95% CI, 0.37–0.46]).CONCLUSIONS:Although there is no differential effect of thrombolysis type on patient-reported global HRQOL and EQ 5D-5L index values in patients with acute stroke, sex- and age-related differences in HRQOL were noted in this study.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT03889249.
peripheral vascular disease,clinical neurology